April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ‌of psychedelic ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Shares of biotech firms and companies providing psychedelic-assisted therapy surged on ...

Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic treatments and increased ...

A PSYCHEDELICS ‘BREAKTHROUGH’? The list of products receiving FDA Commissioner Marty Makary’s priority review vouchers will grow this week to include three psychedelic drugs after a White House ...

Ibogaine's potential to treat symptoms of traumatic brain injuries has been heightened by veterans who have gone to clinics in Mexico. Ibogaine — a potent drug that sends users on an intense, ...

Trump's order on psychedelics sent stocks in the space soaring on Monday. Trump signed an executive order to loosen restrictions in order to hasten the development for medical use. The news boosted ...

April 21 (Reuters) - U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The U.S. Food and Drug Administration (FDA) said Friday it will ...

The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The agency also allowed an early phase clinical study of noribogaine ...

Some psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health treatments in the United States. The US Food and Drug Administration on ...

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest ...